To Top
0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


The information contained in the Organizational Database (ODB) is provided for informational purposes only. There is no implied endorsement by NORD. NORD does not promote or endorse participation in any specific organization. The information is subject to change without notice. Every effort is made to ensure that the details for each entry are as current as possible.

Foundation for Angelman Syndrome Therapeutics (FAST)


P.O. Box 608
Downers Grove, IL 60515-0608





800 Number


Email Address

[email protected]


The Foundation for Angelman Syndrome Therapeutics (FAST) is an all voluntary organization of families and professionals dedicated to finding a cure for Angelman syndrome and related disorders through the funding of research, education, and advocacy. FAST’s goal is to bring practical treatment into current medical practice as quickly as possible and to fund grants that will lead to additional research support from government agencies and other funding sources. Angelman syndrome (AS) is a rare genetic neurological disorder characterized by global developmental delays, learning disabilities, and severe speech impairment. Other symptoms include an inability to coordinate voluntary movements (ataxia) and tremulous, jerky movements of the arms and legs; a distinct behavioral pattern characterized by a happy disposition and unprovoked episodes of laughter and smiling, often at inappropriate times; seizures, sleep disorders and feeding difficulties. Some affected children may have distinctive facial features.

Please Note

The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.

NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.